Clinical Trial Update: Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001 [Phase 1]

View source ↗

Summary

Phase 1 study examining the pharmacokinetic interaction and safety of inhaled CHF5259 and CHF6001 in chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF5259
• CHF6001

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Copd | Phase 1 | Status: COMPLETED